Trial Profile
Clinical study to investigate the efficacy and the safety of R-FM for recurrent or refractory indolent B-cell lymphoma - THF016.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Mitoxantrone (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 21 Apr 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 17 May 2012 Additional trial investigator identified as reported by University Hospital Medical Information Network - Japan.
- 02 Jun 2011 New trial record